Kim Irene K, Choi Jua, Vo Ashley, Kang Alexis, Steggerda Justin, Louie Sabrina, Haas Mark, Mirocha James, Cohen J Louis, Pizzo Helen, Kamil Elaine S, Jordan Stanley C, Puliyanda Dechu
Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Department of Pathology and Laboratory Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Pediatr Transplant. 2017 Dec;21(8). doi: 10.1111/petr.13042. Epub 2017 Sep 19.
ABMR remains a significant concern for early graft loss, especially for those who are HS against HLA antigens. We sought to determine the risk factors leading to ABMR in HS pediatric kidney transplant recipients. From January 2009 to December 2015, 16 HS pediatric kidney transplant patients at our center (age range 2-21) were retrospectively reviewed for outcomes and risk factors for ABMR. All HS patients received desensitization with high-dose IVIG/rituximab prior to transplant. Two groups were examined: ABMR (n = 7) and ABMR (n = 9). Patient survival was 100%; however, one patient in the ABMR group suffered graft loss from ABMR 16 months post-transplant. ABMR patients had higher Class I PRA at the time of transplant (Class I: 73.1 ± 19.1 vs 49.1 ± 28.3, P = .075), although not statistically significant. ABMR patients were more likely to have a history of transplant nephrectomy (P = .013). The characteristic that most strongly correlated with ABMR was the DSA-RIS (P = .045), a scoring system used to quantify cumulative intensity of all DSA. In conclusion, DSA, as quantified by the RIS at the time of transplant, should be considered as part of the initial allocation strategy and patients with high RIS monitored closely for ABMR post-transplant.
抗体介导的排斥反应(ABMR)仍然是早期移植物丢失的一个重要问题,尤其是对于那些针对HLA抗原存在高敏反应(HS)的患者。我们试图确定导致HS儿科肾移植受者发生ABMR的危险因素。对2009年1月至2015年12月期间在我们中心接受肾移植的16例HS儿科患者(年龄范围2 - 21岁)进行回顾性分析,以评估ABMR的结局和危险因素。所有HS患者在移植前均接受了大剂量静脉注射免疫球蛋白(IVIG)/利妥昔单抗脱敏治疗。研究分为两组:发生ABMR组(n = 7)和未发生ABMR组(n = 9)。患者生存率为100%;然而,ABMR组中有1例患者在移植后16个月因ABMR导致移植物丢失。ABMR组患者在移植时的I类群体反应性抗体(PRA)水平较高(I类:73.1 ± 19.1 vs 49.1 ± 28.3,P = 0.075),尽管差异无统计学意义。ABMR组患者更有可能有移植肾切除术史(P = 0.013)。与ABMR相关性最强的特征是供者特异性抗体风险指数(DSA - RIS)(P = 0.045),这是一种用于量化所有DSA累积强度的评分系统。总之,移植时由RIS量化的DSA应被视为初始分配策略的一部分,对于高RIS患者移植后应密切监测ABMR。